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Background: Carotid artery stenting (CAS) for high-risk anatomic lesions is accepted practice. Neck irradiation and
radiotherapy-induced arteritis are common indications. The clinical outcomes of CAS for radiation arteritis have been
poorly defined.
Methods: A prospective database of patients undergoing CAS at a tertiary referral academic medical center was maintained
from 1999 to 2006. Patients undergoing primary carotid artery stenting for significant atherosclerotic (ASOD) and
radiotherapy (XRT)-induced occlusive disease were analyzed. Life-table analyses were performed to assess time-
dependent outcomes. Cox proportional hazard analysis or Fisher’s exact test was performed to identify factors associated
with outcomes. Data are presented as the mean  SEM unless otherwise indicated.
Results:During the study period, 150 patients underwent primary CAS, 75% with embolic protection. Fifty-eight percent
were symptomatic. One hundred twenty-seven (85%) were treated for ASOD, and 23 (15%) had XRT. The 30-day
all-cause mortality rate was 1% for ASOD and 0% for XRT (PNS); overall survival at 3 years was equivalent. There was
no significant difference in major adverse event rates as defined by the Stenting and Angioplasty with Protection in
Patients at High Risk for Endarterectomy (SAPPHIRE) trial between the groups. The 3-year neurologic event-free rate
was 85% for ASOD and 87% for XRT (PNS). Late asymptomatic occlusions were seen only in XRT patients. The 3-year
freedom from restenosis rate was significantly worse for the XRT group, at 20%, vs 74% for the ASOD group (P < .05).
Likewise, the 3-year patency rate was also worse for the XRT group, at 91%, vs 100% for ASOD by Kaplan-Meier analysis
(P < .05). No factor was predictive of occlusion or stenosis by Cox proportional hazards analysis.
Conclusion: CAS for radiation arteritis has poor long-term anatomic outcome and can present with late asymptomatic
occlusions. These findings suggest that these patients require closer postoperative surveillance and raise the question of
whether CAS is appropriate for carotid occlusive lesions caused by radiation arteritis. ( J Vasc Surg 2007;45:110-7.)Extracranial carotid stenosis as a result of accelerated
atherosclerosis is a recognized complication of external
beam radiation in patients with head and neck malig-
nancy.1-5 Cervical irradiation is a known risk factor for
accelerating carotid stenosis progression.6,7 Carmody et al5
demonstrated a 22% prevalence of70% carotid stenosis in
patients with previous neck radiotherapy compared with 4%
in controls. Eighty percent of patients with significant
stenosis in the irradiated group were symptomatic.5
Carotid endarterectomy (CEA) in these patients is hin-
dered by previous surgical reconstructions and radiation-
induced fibrosis that obliterates the endarterectomy plane
and, as a result, is often associated with interposition graft
placement. Carotid surgery in these patients is not associ-
ated with a greater risk of stroke; however, a higher inci-
dence of arterial damage, cranial nerve palsy, prosthetic
infection, anastomotic breakdown, restenosis, and an in-
creased rate of wound complications have been reported.8
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110These patients are thus at a higher risk than nonirradiated
patents, and as a result, neck irradiation and radiation
arteritis are common high-risk indications for carotid artery
stenting (CAS).
The clinical outcomes of CAS for radiation arteritis are
not well defined and we sought retrospectively to define
our outcomes for primary CAS in radiation arteritis within
our vascular service line.
METHODS
Study setting. This study was performed at the Uni-
versity of Rochester Medical Center, an academic medical
center in a metropolitan area of 300,000 population and a
surrounding rural county of about 1 million in western
New York State. The center is a tertiary referral center with
a dedicated vascular service line.
Experimental design. A prospective database of pa-
tients undergoing endovascular treatment for carotid artery
occlusive disease between 1999 and 2006 was maintained.
Patients undergoing primary CAS for significant athero-
sclerotic (ASOD) and radiotherapy-induced (XRT) occlu-
sive disease were analyzed. Vessels treated for intimal hy-
perplasia or trauma were excluded. Data utilization fell
under the category of secondary use of pre-existing data.
Procedures. Procedures were performed with local
Institutional Review Board approval or as part of an ap-
proved multicenter clinical trial, or both, and followed
Centers for Medicare and Medicaid Services regulations.
For each patient, demographics, symptoms, existing co-
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identified. Periprocedural data were obtained from the
record. Follow-up was by clinical assessment and carotid
duplex ultrasound scans performed at 1, 6, and 12 months
after the intervention and every 6 months thereafter. Pa-
tients underwent carotid stenting where carotid stenosis
80% was detected on duplex imaging and was confirmed
on computed tomography (CTA) or magnetic resonance
angiography (MRA).
Patients were given clopidogrel (75 mg) and aspirin
(81 mg) beginning 3 days before the intervention. Patients
were asked not to take their -blocker medications the day
of the procedure, and we did not begin giving prophylactic
-blockers before the procedure. Patients with a baseline
heart rate of 60 beats/min were given prophylactic atro-
pine. Patients who demonstrated a bradycardia on angio-
plasty before stenting were prophylactically treated. Rou-
tine preprocedural and postprocedural neurology
consultations were not requested unless the patient was
symptomatic.
After the stenting procedure, clopidogrel was contin-
ued for 1 month, and aspirin was continued for life. All
patients undergoing carotid stenting received an intrave-
nous heparin bolus (100 U/kg) to achieve systemic anti-
coagulation during the carotid intervention.
All carotid stenting procedures were performed in
fixed-imaging procedure rooms under conscious sedation.
The technique of stenting with an embolic protection
device has been described previously.9 A self-expanding
monorail carotid stent was deployed across the internal
carotid stenosis and consisted of Wallstent (Boston Scien-
tific, Natick, Mass) Precise (Cordis, Miami Lakes, Fla), or
Acculink (Guidant, Santa Clara, Calif) stents. Balloon an-
gioplasty after stenting was performed with an angioplasty
balloon (diameter, 5 or 6 mm), depending on the appear-
ance of the completion angiogram.
Patients were routinely kept in the hospital overnight
and discharged home the next day. Follow-up visits with
carotid duplex ultrasound scans were performed as previ-
ously indicated. Patients who required interventions for
clinically significant restenosis after CAS were evaluated
with duplex ultrasound scans at 3-month intervals. We did
not perform immediate duplex scanning in the periopera-
tive period. All duplex ultrasound scans were performed at
approved vascular laboratories accredited by the Intersoci-
ety Commission on Accreditation of Vascular Laboratories
using the University of Washington criteria.
Restenosis was defined as the development of 50%
stenosis. Clinically significant stenosis was defined as lumi-
nal reduction of 80% or higher. The presence of a high-
grade stenosis was verified by biplanar carotid angiography.
Patients that were defined as restenosed by University of
Washington criteria were subsequently re-evaluated using
modified criteria for in-stent restenosis by Stanziale et al,10
peak systolic velocity225 cm/s and internal carotid artery
(ICA)/common carotid artery (CCA) 2.5 for 50%
stenosis.Carotid angioplasty and possible stenting were subse-
quently performed by following the standard protocol
upon confirmation of the restenotic lesions. Patients with
50% stenosis and no symptoms were monitored. Patients
with80% stenosis or50% stenosis with symptoms were
offered angiography. Our policy is to watch restenosis
80% that is asymptomatic. Reintervention was offered to
patients with 80% stenosis.
Definitions. The XRT patients were defined as having
irradiation directed at head and neck cancers and XRT had
been received for 17 laryngeal cancers, 4 lymphomas, 1 oral
cancer, and 1 parotid cancer. Coronary artery disease was
defined as a history of angina pectoris, myocardial infarc-
tion, congestive heart disease, or prior coronary artery
revascularizations. Cerebrovascular disease included a his-
tory of stroke, transient ischemic attack (TIA), or carotid
artery revascularization. Hypertension was defined as a
systolic blood pressure 150 mm Hg or diastolic blood
pressure90mmHg on three occasions during a 6-month
period. Hyperlipidemia was defined as fasting cholesterol
200 mg/dL, a low-density lipoprotein cholesterol of
130 mg/dL or triglycerides 200 mg/dL, or active
therapy for hyperlipidemia. Diabetes was defined as a fast-
ing plasma glucose110mg/dL, anHbA1c7%, or active
therapy for diabetes. Metabolic syndrome was defined as
previously described,11 with the exception of abdominal
circumference, which is not routinely recorded. We substi-
tuted a body mass index score 27.0 as a positive score
instead of an abdominal circumference 102 cm for men
or 88 cm for women.
A death 30 days of the procedure was considered
procedure-related. Amajor complication was defined as any
event, regardless of how minimal, not routinely observed
after endoluminal therapy that required treatment with a
therapeutic intervention or rehospitalization 30 days of
the procedure. The major adverse event rate was defined
using Stenting and Angioplasty with Protection in Patients
at High Risk for Endarterectomy (SAPPHIRE) criteria.12
Unlike SAPPHIRE, patients did not have a troponin series
performed or formal neurologic consultations.
Primary patency was defined as a patent carotid seg-
ment without recurrent stenosis or the need for further
intervention. Assisted primary patency was defined as a
patent carotid segment, which underwent further interven-
tion within the inflow, treated vessel segment or outflow of
the treated vessel segment to improve patency. Secondary
patency was defined as an occluded carotid vessel or a
carotid with hemodynamic failure resulting in a surgical
bypass. Loss of patency was defined according to accepted
Society of Vascular Surgery (SVS) reporting standards.
Statistical analysis. All statistical analyses were per-
formed on an intention-to-treat basis. Measured values are
reported as percentages or means  1 SD. Survival, pa-
tency, and neurologic-free and major adverse event rates
were calculated using Kaplan-Meier analysis and are re-
ported using current SVS criteria. Standard errors are re-
ported in Kaplan-Meier analyses. The log-rank test was
used to determine differences between life tables. Multivar-
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influence of preprocedural and periprocedural factors on
outcomes.
The significance level P  .10 was used to include or
eliminate a covariate from the model. Covariates were
considered to be significantly associated with the outcome
if they were included in the final model and their signifi-
cance level was P  .05. Interactions between statistically
significant covariates were checked. Logistic regression
models were used for outcomes that were measured shortly
after the procedure (complications, short term clinical ben-
efits). The dependence of each covariate on the outcome
was first checked separately using the 2 test. Covariates
with the significance level of P  .10 were included in the
multivariate stepwise analysis.
RESULTS
Patient population. During the study period, 150
patients (60% men) underwent primary CAS, 75% with
embolic protection; 58% of these patients were symptom-
atic. The most common presenting symptom was TIA
(36%), followed by cerebrovascular accident (31%), verte-
brobasilar stroke (19%), and amaurosis fugax (14%). No
statistical differences were present between groups for
symptoms (Table I). A total of 127 (85%) were treated for
ASOD, and 23 (15%) had XRT. The mean age was 71 
0.03 years (range, 46 to 95 years) for ASOD patients and
71 0.12 years (range: 56 to 85 years) for XRT patients (P
NS). Among the comorbidities between the two groups,
only hypothyroidism was found to be significantly different
(Table II).
The mean length of follow-up was 14.4 months. Pre-
operative evaluations consisted of ultrasound imaging only
(45%); ultrasound imaging with MRA (20%), CTA (12%),
or angiography (4%); ultrasound imaging, MRA, and CTA
(2%); MRA and angiography (4%); MRA alone (3%), and
angiography alone (6%).
Preoperative hemodynamics evaluated the degree of
Table I. Patient characteristics*
ASOD
n  127(%)
XRT
n  23(%)
Age years (mean  SD) 71  11 71  8
 80 years 28 (22) 4 (17)
Sex (male) 76 (60) 14 (61)
Symptoms
Asymptomatic 55 (43) 12 (52)
Stroke 26 (20) 3 (13)
Transient ischemic attack 29 (23) 5 (22)
Amaurosis fugax 10 (8) 3 (13)
Vertebrobasilar stroke 17 (9) 1 (4)
Contralateral Lesion
50% Stenosis 49 (39) 11 (48)
80% Stenosis 20 (16) 6 (26)
ASOD, patients with atherosclerotic occlusive disease; XRT, patients with
radiotherapy-induced arteritis.
*P  NS for all data.vessel stenosis as occluded (0%), 80% to 99% stenosis (84%),70% to 79% stenosis (14%), and 50% to 69% stenosis (2%).
Sixty patients (40%) presented with contralateral disease
50%, and 26 (17%) presented with contralateral disease
80% (no difference between groups). No patients pre-
sented with vessel occlusion. There was a positive correla-
tion between preoperative ultrasound imaging and intraop-
erative angiography.
Procedures. Procedural details are shown in Table III.
The 30-day all-cause mortality rate was 1% for ASOD and
0% for XRT (P  NS), and overall survival at 3 years was
equivalent. There was no significant difference in major
adverse event rates, as defined by the SAPPHIRE trial, or
local complications between the two groups.
Table IV describes the frequency of systemic, regional,
Table II. Patient Comorbidities*
ASOD
n  127(%)
XRT
n  23(%)
Coronary artery disease
Congestive heart failure 38 (30) 8 (35)
Myocardial infarction 60 (47) 9 (39)
Atrial fibrillation 13 (10) 1 (4)
COPD 25 (20) 3 (13)
Hypertension 119 (94) 22 (96)
Diabetes mellitus
Insulin dependent 7 (6) 0 (0)
Noninsulin dependent 42 (33) 4 (17)
Hyperlipidemia 107 (84) 18 (78)
Metabolic syndrome 58 (46) 9 (39)
Renal insufficiency
Creatinine 1.5 mg/dL 35 (28) 3 (13)
Hemodialysis dependent 2 (2) 0 (0)
Hypothyroid* 22 (17) 15 (65)
Nicotine abuse
Current 25 (20) 1 (4)
Former 84 (66) 18 (78)
No history 18 (14) 4 (17)
Body mass index (kg/m2)
 27.0 72 (57) 8 (35)
 30.0 42 (33) 5 (22)
ASOD, patients with atherosclerotic occlusive disease; XRT, patients with
radiotherapy-induced arteritis; COPD, chronic obstructive pulmonary dis-
ease.
*P  NS except for hypothyroid (P  .05).
Table III. Procedure
ASOD
n  127(%)
XRT
n  23(%) P
Lesion location
Common carotid only 14 (11) 6 (26) NS
Internal and common carotids 4 (3) 6 (26) .05
Internal carotid only 105 (83) 10 (44) .05
Technical failure 4 (3) 1 (4) NS
Embolic protection device
Successful deployment 101 (93) 11 (92) NS
Unsuccessful deployment 8 (7) 1 (8) NS
ASOD, patients with atherosclerotic occlusive disease; XRT, patients with
radiotherapy-induced arteritis.and local complications encountered perioperatively.
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(13%), hypotension (9%), vasospasm (9%), hematoma
(5%), stroke (5%), and TIA (4%). Four procedures (3%) for
ASOD and one procedure (4%) for XRT resulted in tech-
nical failure (P  NS). Disease was more extensive in the
XRT group: 3% of ASOD stenoses and 26% of XRT steno-
ses involved the ICA and CCA (P  .05). Successful
deployment of embolic protection devices was achieved in
93% and 92% of attempts for ASOD and XRT, respectively
(P  NS). There was no difference in residual stenosis of
30% between the two groups, 97% of ASOD and 96% of
XRT, as determined by the completion angiogram.
Table IV. Complications*
ASOD
n  127(%)
XRT
n  23(%)
Systemic
Cardiac (MI) 2 (2) 0 (0)
Pulmonary 3 (2) 0 (0)
Renal 2 (2) 0 (0)
Regional
Stroke 7 (6) 1 (4)
TIA 7 (6) 0 (0)
Bradycardia 18 (14) 2 (9)
Hypotension 14 (11) 0 (0)
Vasospasm 12 (9) 2 (9)
Local
Dissection 2 (2) 0 (0)
Occlusion 0 (0) 0 (0)
Hematoma 7 (6) 1 (4)
Groin AV fistula 0 (0) 0 (0)
Groin hemorrhage 1 (1) 0 (0)
Groin pseudoaneurysm 2 (2) 0 (0)
ASOD, patients with atherosclerotic occlusive disease; XRT, patients with
radiotherapy-induced arteritis; MI, myocardial infarction; TIA, transient
ischemic attack; AV, arteriovenous fistula
*P  NS.
Table V. Clinical outcomes
ASOD n 
Technical failure 4 (
Restenosis of all patients 16 (
Years to restenosis, mean  SD 1.0 
Restenosis of patients* 12 (
Years to restenosis, mean  SD 1.33 
Vessel occlusion 0 (
Years to occlusion, mean  SD 0
Reintervention(s) 1 (
Recurrent symptoms 19 (
Cerebrovascular accident
30 days 9 (
During entire length of follow-up 13 (
Myocardial infarction
30 days 0 (
During entire length of follow-up 4 (
Mortality
30 days, all causes 1 (
During entire length of follow-up 1 (
ASOD, patients with atherosclerotic occlusive disease; XRT, patients with r
*Excluding technical failures.Outcomes. During follow-up, the rate of restenosis
was 13% for ASOD and 43% for XRT (P  .05), with an
average time to restenosis of 1.0  0.01 years and 0.8 
0.04 years, respectively (P  NS) (Table V). Freedom from
restenosis was significantly worse for the XRT group, with
rates of 55%, 39%, and 32% at 1, 2, and 3 years, respectively,
vs 89%, 82%, and 72% for the ASOD group (P  .05) (Fig
1). For the patients who restenosed, five of the 16 ASOD
and four of the 10 XRT patients had a prior postoperative
duplex ultrasound examination that showed freedom from
restenosis (Fig 2). Vessel occlusion only occurred in the
XRT group (8.6% vs 0% for ASOD patients; P  .05) (Fig
3). The two vessel occlusions in the XRT group occurred at
0.8 and 1.9 years; one was symptomatic, with episodes of
visual field loss, and the other was asymptomatic (Table V).
Fig 1. Freedom from restenosis. Sixteen (13%) patients with ath-
erosclerotic occlusive disease (ASOD) and 10 patients (43%) with
radiotherapy-induced (XRT) arteritis restenosed (P  .05). The
3-year rates for freedom from restenosis were 74% for ASOD and
20% for XRT. Error bars are omitted for clarity. The number of
procedures at risk at each time interval is shown below the figure.
The standard error did not exceed 10% at all time intervals that
were analyzed.
(%) XRT n  23(%) P
1 (4) NS
10 (43) .05
0.83  0.67
9 (39) .05
0.92  0.66
2 (8.6) .05
1.34  0.77
3 (13) .05
4 (17) NS
2 (9) NS
2 (9) NS
0 (0) NS
1 (4) NS
0 (0) NS
2 (9) NS
erapy-induced arteritis.127
3)
13)
1.81
9)
1.96
0)
1)
15)
7)
10)
0)
3)
1)
1)
adioth
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and neck irradiation (relative risk, 3.0) hypothyroidism
(relative risk, 2.3), and insulin-dependent diabetes mellitus
(relative risk, 2 10–6) altered the rate of restenosis among
patients; all other patient characteristics, comorbidities, and
presenting symptoms were insignificant risk factors for
increasing the likelihood of restenosis.
The respective symptom-free rate at 1, 2, and 3 years
was 87%, 85%, 85% for ASOD, respectively, and 87%, 87%,
87% for XRT (Fig 4). During the entire length of follow-
up, the rate of recurrent symptoms was 16% for ASOD and
17% for XRT (PNS). Cerebrovascular accident30 days
of procedure did not differ between ASOD (9, 7%), and
XRT (2, 9%; P  NS). Only one death, which was in the
Fig 2. Freedom from restenosis, assisted. One patient with ath-
erosclerotic occlusive disease (ASOD) and three patients with
radiotherapy-induced (XRT) arteritis underwent reintervention.
Restenosis rates remained significantly different between the two
groups. Error bars are omitted for clarity. The number of proce-
dures at risk at each time interval is shown below the figure.
Standard error did not exceed 10% at all time intervals that were
analyzed.
Fig 3. Vessel patency. No patient (0%) with atherosclerotic oc-
clusive disease (ASOD) and two patients (8.6%) with radiotherapy-
induced (XRT) arteritis occluded postoperatively (P  .05). The
3-year rates for freedom from occlusion were 100% for ASOD and
79% for XRT. Error bars are omitted for clarity. The number of
procedures at risk at each time interval is shown below the figure.
Standard error did not exceed 10% at all time intervals that were
analyzed.ASOD group, occurred 30 days of the procedure (P NS) (Fig 5). Only one ASOD patient (1%) required rein-
tervention, whereas three XRT patients (13%) underwent
reintervention (P  .05). The three XRT patients were
stented again, and the one ASOD patient underwent a
common carotid cut-down and cryoplasty. Two of the
reinterventions were for in-stent restenosis, and the third
was for 99% stenosis proximal to the stent. The three
patients that required reintervention all had excellent ana-
tomic outcomes on final postoperative imaging during the
original procedure. All three patients were asymptomatic
before reintervention. Assisted patency rates remained sig-
nificantly different between the two groups (Figs 2 and 3).
DISCUSSION
General. Patients with a past history of head and neck
irradiation are thought to be poor candidates for CEA
Fig 4. Freedom from recurrent symptoms. Twenty patients
(16%) with atherosclerotic occlusive disease (ASOD) four patients
(17%) with radiotherapy-induced (XRT) arteritis experienced re-
current symptoms postoperatively (P  NS). Error bars are omit-
ted for clarity. The number of procedures at risk at each time
interval is shown below the figure. Standard error did not exceed
10% at all time intervals that were analyzed.
Fig 5. Patient survival. One patient (1%) with atherosclerotic
occlusive disease (ASOD) and two (9%) with radiotherapy-induced
(XRT) arteritis died during follow-up (P  NS). Error bars are
omitted for clarity. The number of procedures at risk at each time
interval is shown below the figure. Standard error did not exceed
10% at all time intervals that were analyzed.owing to the loss of fascial planes from radiation-induced
an: 40
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lence of carotid artery stenosis among patients who previ-
ously underwent head and neck radiotherapy.1-5 The pro-
portion of patients who were previously irradiated and later
developed significant carotid stenosis ranged from 18%
through 7.5 years of follow-up as reported by Brown et al,1
to 40% through 10 years of follow-up as reported by Steele
et al.4
The literature is conflicting on whether endovascular
stenting or endarterectomy/bypass is most effective (Ta-
bles VI and VII). Some reports indicate CEA for previously
irradiated patients is acceptable and results in the same
outcomes as for nonirradiated patients.13-16 Friedell et al13
reviewed their experience in treating 13 previously irradi-
ated patients with CEA for carotid artery stenosis. There
were no perioperative deaths, cranial nerve injuries, or
cerebral infarctions, and after an average follow-up of 37
months, all remained living and asymptomatic, with one
vessel occlusion. Kashyap et al14 treated 24 previously
irradiated patients. They also found no perioperative deaths
or cerebral infarctions, and over the course of follow-up, no
CVAs, one occlusion, two restenoses, and one reinterven-
tion occurred.
In the largest study, by Lesèche et al,15 27 previously
irradiated patients were followed-up and one perioperative
death owing to hemorrhage and one TIA occurred. All
patients remained asymptomatic throughout follow-up,
and the risk of recurrent stenosis at 18 months was 16.6%,
with two vessels requiring reintervention.15 Rockman et al
treated nine previously irradiated patients with the follow-
Table VI. Carotid artery stenting for radiation-induced st
Houdart et al18 Ti
Patients (N) 7
EPD 2/7 
Peri-op mortality 0/7 
Peri-op morbidity 1/7
Stroke rate 0/7
Freedom from recurrence 100% 
Patency 100%
Reintervention(s) 0
Follow-up (months) Mean: 8 M
EPD, embolic protection device
Table VII. Carotid endarterectomy for radiotherapy-indu
Kashyap et al14 L
Patients (N) 24
Peri-op mortality 0/24
Peri-op morbidity 10/24
Stroke rate 0/24
Freedom from recurrence 21/24
Reintervention(s) 1
Patency rate 96%
Follow-up 1-156 months Meing outcomes: no perioperative mortality, one periopera-tive stroke, one procedural complication (a carotid artery
pseudoaneurysm), and no signs of recurrent stenosis during
follow-up.16 A recent Cochrane Systematic Review con-
cluded no significant difference betweenmajor risk of treat-
ment for CAS and CEA.17
Meanwhile, other authors suggest carotid stenting is
safe and comparable to surgical intervention for radiother-
apy-induced stenoses. Both Houdart et al,18 who moni-
tored seven XRT patients for a mean of 8 months, and
Al-Mubarak et al,19 who monitored 14 XRT patients for 6
months, found 100% of the patients free of restenosis and
no reinterventions performed during the course of follow-
up. Ting et al20 and Harrod-Kim et al21 both monitored 16
XRT patients for 30 and 28 months, respectively, and
found the freedom from recurrence was 82.4% and 79%,
respectively. Our findings differ greatly. With a mean fol-
low-up of 14.4 months, 57% of our XRT patients were free
from restenosis.
We sought to find a reason why our restenosis rates
differed from these authors. There was no difference in
defining restenosis as 50%. The difference between our
findings and those of Houdart et al18 and Al-Mubarak et
al19 could result from the differences in length of follow-
up. Houdart et al lost 36% of their patients to follow-up,
whereas our rate, at 17%, was less than half. Their patients
may not have been given enough time to restenose; how-
ever, Ting20 and Harrod-Kim21 both monitored their pa-
tients for twice the duration and found freedom of recur-
rence rates for their XRT patients to be comparable with
is—literature review
al20 Harrod-Kim et al21 Al-Mubarak et al19
16 14
0/16 *
6 1/16 0/14
6 2/16 1/14
6 1/16 1/14
 82.4% 79%
88% 100%
3 0
: 30 Mean: 28 6
tenosis—literature Review
 et al15 Friedell et al13 Rockman et al16
7 10 10
27 0/10 0/10
27 0/10 2/10
27 0/10 1/10
27 9/10 10/10
2 0 0
0% 90% 100%
months Mean: 37 months 1-5 yearenos
ng et 
16
* 
0/1
4/1
1/1
100%
100%
1
edianced s
eseche
2
1/
3/
0/
24/
10our ASOD patients.
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nical failures as immediate restenosis. By excluding techni-
cal failures, our restenosis rate drops to 39%, and Ting et al,
when including technical failures, increases to 22%.
Harrod-Kim et al21 calculated their freedom from resteno-
sis based on the number of occlusions out of total vessels
stented. If a patient had the CCA and ICA stented, then we
would view this intervention as having the potential for one
future restenosis, rather than two vessels with the potential
to restenosis. The interventions for our 23 XRT patients
were 10 ICA only, six CCA only, and six CCA and ICA.
Thus, 28 vessels were stented, and our restenosis rate
would become 36% when including technical failures, and
32% when not including technical failures. Our reported
43% restenosis rate for XRT patients does drop when we
apply the same approach as the mentioned authors, but a
significant difference still exists between our ASOD and
XRT patients regardless of the approach taken. This differ-
ence between ASOD and XRT patients was not examined
by the previous four studies. Although our XRT restenosis
rates are higher than the 0% to 21% reported elsewhere,
these studies do not provide a baseline restenosis rate for
their ASOD patients.
With the idea of whether a true group of high-risk
patients exists, for whomCEAmay not be ideal for and thus
should be managed endovascularly, we found it pertinent
to determine our effectiveness in endovascularly treating a
subset of the high-risk group, irradiated patients.22
Procedural events. Four of the five technical failures
were the result of vessel tortuosity, and the fifth procedure
was terminated owing to the fear of disrupting the extensive
plaque formation and the patient exhibiting severe nausea
and retching. No difference existed in the success rate of
embolic protection device deployment between the two
groups. However, XRT patients were significantly more
likely to not have deployment of an embolic protection
device attempted, 48% (XRT) vs 14% (ASOD). Some of
this reflects that fact that these patients were treated before
the clinical release of embolic protection devices.
Others have found XRT patients to exhibit a higher
prevalence of bilateral disease and a higher rate of CCA
lesions.3 We did not find a significant difference between
the two groups with respect to CCA lesions; however, we
did find the XRT patients to have more extensive disease
within the carotid artery (ie, involving both the ICA and
CCA). The only significant factor for predicting postoper-
ative stroke was if an attempt to deploy the embolic protec-
tion device was unsuccessful. A successful deployment of an
embolic protection device was not seen as protective, and
not attempting placement of an embolic protection device
was not seen as a risk factor for postoperative stroke. No
differences existed between the two groups with regards to
systemic complications, regional complications at the ca-
rotid artery and brain, or local complications at the access
site.
Although not significantly different from the ASOD
group, none of the XRT patients became hypotensive dur-
ing the procedure. Perhaps this was due to the lack oflesions at the carotid bulb in the XRT group, or that the
previous cervical irradiation damaged the glossopharyngeal
and resulted in a loss of the baroreceptor reflex. Our two
most common perioperative complications, bradycardia
(13%) and hypotension (9%), were roughly half the rate in
previous reports.23,24 Among the patient comorbidities
screened, only hypothyroidism differed significantly be-
tween the two groups. A greater proportion of hypothyroid
patients (65%) were in the XRT group vs the ASOD group
(17%), which was expected owing to the XRT patients’
previous history of neck irradiation.
Cumulative patency. No significant difference was
found in the proportion of technical failures between the
two groups; however, even if the technical failures are
excluded from analysis, the freedom from restenosis still
differs significantly between ASOD and XRT patients. One
ASOD patient (1%) required reintervention at 3.4 years
after operation, and the vessel remained patent at the last
follow-up. Meanwhile, three XRT (13%) patients required
reintervention at 0.08, 0.89, and 4.26 years after operation.
All three patients restenosed again for a second time, and
one required reintervention for a second time. It is of
interest that despite a roughly threefold greater rate in
vessel restenosis and a significant difference in reinterven-
tion rates, no difference existed in rate of recurrent symp-
toms between groups.
The rates for freedom from recurrent symptoms at 1, 2,
and 3 years were, respectively, 87%, 85%, 85% for ASOD,
and 87%, 87%, 87% for XRT (P  NS). Of the patients
experiencing recurrent symptoms, CVAs occurred in 13,
TIAs in 4, both upper extremity paresthesia and episodes of
aphasia in 2, and 1 patient each had perioperative CVA and
later a left homonymous hemianopsia, loss of auditory
function, upper extremity paresthesia, and an episode of
aphasia.
There have been discussions that the current guidelines
for evaluating in-stent restenosis are insufficient and over-
estimate restenosis.10,25 Because all of our patients were
stented, both groups should be equal in the proportion of
overestimates. We chose to follow recommendations from
Stanziale et al10 and used 225 cm/s and an ICA/CCA
2.5 as the cutoffs for 50% stenosis.10 Using the new
criteria, five ASOD and one XRT patient were excluded
from the restenosis population, resulting in 9% of ASOD
and 39% of XRT patients restenosing (P  .05).
CONCLUSION
Technical failure and 30-day event rates are similar
among ASOD and XRT patients. CAS is equally as effective
in preventing recurrent symptoms in XRT patients as in
ASOD patients. However, XRT patients show increased
rates of restenosis, reintervention, and occlusion. CAS for
radiation arteritis has poor long-term anatomic outcome
and can present with late occlusions. These findings suggest
that these patients require closer postoperative surveillance
and raise the question of whether CAS is appropriate for
carotid occlusive lesions caused by radiation arteritis.
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